Compound ID | 991
Class: Aminocoumarin
| Agent Type: | Natural product; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | DNA synthesis inhibitor. Bacterial topoisomerase inhibitor |
| Target Pathogen: | Active against Staphylococcus aureus |
| Combined with other compounds: | Tested in combination with ciprofloxacin for the treatment of S.aures infections, no synergistic effect observed. |
| Propensity to select resistant mutants: | Coumermycin resistant mutants could be selected in vitro in 15 S.aureus strains tested in |
| Description: | Grunberg, E., R. Cleeland, and E. Titsworth. "Further observations on chemotherapeutic activity of coumermycin A1. I. Activity against Neisseria meningitidis type A and meningopneumonitis." Antimicrobial agents and chemotherapy 6 (1966): 397. |
| Year first mentioned: | 1966 |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
| Reason dropped: | Weak bactericidal activity at high concentration despite reasonable bacteriostatic activity at lower concentrations; poorly absorbed from gastrointestinal tract |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/54675768 |
| Guide to Pharmacology: | coumamycin |
| Citations: |
|